ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing
ProMIS Neurosciences reported a Q3 2026 net loss of $8.2 million, or $(0.89) per share, with cash of $44.1 million as of September 30, 2026. The company reaffirmed that PRECISE-AD Phase 1b topline data for PMN310 remains on track for Q1 2027, and said cash funds operations through 2027 — beyond the readout. Interim data showed no ARIA-E and encouraging biomarker signals.
Key figures
- Guidance
- PRECISE-AD unblinded 12-month topline data on track for Q1 2027; registrational study anticipated toward end of 2027
- Runway
- through 2027
- Net loss q3
- 8161868
- Cash position
- 44100000
- Ga expense q3
- 1905389
- Rd expense q3
- 6710035
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.